SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QCOR Questcor Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw11/2/2012 10:46:26 AM
  Read Replies (1) of 107
 
Questcor Pharmaceuticals (QCOR) Slammed as Cerium Pharmaceuticals Granted FDA Orphan Drug Status 9:50 AM ET, 11/02/2012 - Street Insider

Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) is under heavy pressure early Friday which is related to reports Cerium Pharmaceuticals received FDA orphan drug designation for Synacthen Depot, the synthetic equivalent of Acthar.

Shares of QCOR last traded at $23.79, down 6.5 percent.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News